OSCR
Oscar Health, Inc.
OSCR has the edge over SGRY overall, supported by stronger fundamentals and stronger modeled upside.
SGRY
Surgery Partners, Inc.
SGRY has slightly lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SGRY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weak |
SGRY's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
SGRY PE Valuation
SGRY has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over SGRY on the outlook, with more favorable earnings and revenue expectations.
SGRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect SGRY's revenue and profitability to decline, with its earnings holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over SGRY on earnings quality, reporting a profit while its opponent remains loss making.
SGRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | — |
| Q3 2026 | -$0.67 | +$0.69 |
| Q2 2026 | -$0.69 | +$0.74 |
| Q1 2026 | -$0.59 | +$0.94 |
| Q4 2025 | -$0.61 | +$0.72 |
| Q3 2025 | -$1.36 | -$0.89 |
| Q2 2025 | -$1.43 | -$1.17 |
| Q1 2025 | -$1.53 | -15400% |
| Q4 2024 | -$1.33 | -$1.24 |
SGRY is still losing money, but far less than before: $0.67 per share over the past year, against $3.67 at its worst in late 2020.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SGRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
SGRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $815.3M | -0.8% |
| Q2 2026 | $848.9M | +2.7% |
| Q1 2026 | $810.9M | +4.5% |
| Q4 2025 | $885M | +2.4% |
| Q3 2025 | $821.5M | +6.6% |
| Q2 2025 | $826.2M | +8.4% |
| Q1 2025 | $776M | +8.2% |
| Q4 2024 | $864.4M | +18% |
SGRY's revenue grew through 2024 and has held roughly level since: $815M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -2.4 points |
| Q2 2026 | 12% | -1.5 points |
| Q1 2026 | 8.1% | +0.1 points |
| Q4 2025 | 12% | -2.3 points |
| Q3 2025 | 13% | +5 points |
| Q2 2025 | 14% | +2.4 points |
| Q1 2025 | 8% | -2.6 points |
| Q4 2024 | 15% | +0.9 points |
SGRY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
SGRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $79M | +24% |
| Q2 2026 | $37.5M | -35% |
| Q1 2026 | -$4.3M | +$12.4M |
| Q4 2025 | $90.6M | +1.7% |
| Q3 2025 | $63.8M | +42% |
| Q2 2025 | $57.9M | +3.6% |
| Q1 2025 | -$16.7M | -185% |
| Q4 2024 | $89.1M | +108% |
SGRY generated $203M in free cash flow over the past year, up 4.5% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SGRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +40K shares |
| 1 year | +1.3% | +1.7M shares |
| 3 years | +2.5% | +3.1M shares |
| 5 years | +86% | +59.6M shares |
| Available history | +167% | +80.6M shares |
SGRY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over SGRY on leverage, with a lower net debt burden relative to earnings.
SGRY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.0x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 6.2x | High |
| Q4 2025 | 6.1x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 6.4x | High |
| Q1 2025 | 6.8x | High |
| Q4 2024 | 6.2x | High |
SGRY's net debt is about 5.0 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SGRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.5 | Overbought |
| Stochastic | 97.4 | Overbought |
SGRY's weekly RSI is 79 (overbought) and its Stochastic is 97 (overbought).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SGRY PE vs Healthcare Sector
| Metric | SGRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SGRY has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
SGRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 47% above |
| 20 week MA | $16.3 | 63% above |
| 50 week MA | $15.2 | 75% above |
| 100 week MA | $18.6 | 43% above |
| 200 week MA | $25.0 | 6.5% above |
SGRY has climbed back above all five of its weekly moving averages, and it's now 6.5% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SGRY on returns for 2026, with the stronger performance.
SGRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.5 | $27.8 | +79% |
| 2021 | $27.8 | $53.5 | +92% |
| 2022 | $53.5 | $26.7 | -50% |
| 2023 | $26.7 | $32.0 | +20% |
| 2024 | $32.0 | $20.9 | -35% |
| 2025 | $20.9 | $15.9 | -24% |
| 2026 YTD | $15.9 | $26.6 | +67% |
SGRY is up 67% so far in 2026, after finishing lower in three of the previous six years.